18 Mar 2013 07:00
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or "the Company")
DIRECTORATE CHANGE
Advanced Oncotherapy (AVO) is pleased to announce the appointment of Dr Chris Boshoff as a non-executive director of the Company. Dr Boshoff replaces Keith Gibbs, Chief Executive of AXA PPP Healthcare, who has resigned from the Company.
Dr Chris Boshoff is Professor of Cancer Medicine at UCLH, and Director of the UCL Cancer Institute. He trained in Medicine in South Africa, and specialised in Medical Oncology at the Royal London, Royal Free, Royal Marsden and University College London Hospitals. He completed a PhD in Viral Oncology at the Institute of Cancer Research, London. He is a Fellow of the Royal College of Physicians (FRCP), and a Fellow of the Academy of Medical Sciences (FMedSci). Dr Boshoff has published extensively in peer reviewed journals including Nature, Lancet Oncology and The New England Journal of Medicine.
There is no further information required to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.
Commenting on the Board change, Lord David Evans, Non-Executive Chairman, said "Keith has made a huge contribution to the success of the Company over his 9 years as a director. May I offer very sincere thanks, on behalf of the board. We are very grateful for his expertise and guidance and wish him well".
Keith Gibbs, commenting on his resignation, said "This is an ideal opportunity for me to move on as AVO begins its decisive move into cancer services. This exciting new phase will transform the Company to a leader in cancer care services."
Commenting on this new appointment, Dr Mike Sinclair, Chief Executive, said "We welcome Dr Boshoff and his research expertise to assist us in evaluating commercial opportunities for new technology to improve cancer treatment. He brings with him a rare perspective because he uniquely combines a world class reputation for cancer research with patient care at UCLH."
For further information, please contact:
Michael Sinclair, Chief Executive | Sandy Jamieson | Jon Levinson | Simon Hudson, |
| Advanced Oncotherapy Group Plc | Libertas Capital Corporate Finance Ltd | Peterhouse Corporate Finance | Tavistock Communications |
| 0203 617 8739 | (NOMAD & Joint Broker) | (Joint Broker) | (Financial PR & IR) |
| 020 7569 9650 | 020 7469 0930 | 020 7920 3150 |
About Advanced Oncotherapy
Advanced Oncotherapy is a provider of new technology for innovative and patient-focused cancer treatments in the UK. These are technologies endorsed internationally by UK and global cancer clinicians, but not currently available in the NHS nor the private sector. Such initiatives build on the Group's 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its Oncotherapy Resources business focused on early stage breast cancer treatment. Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK. They have secured planning approval for its first proton beam therapy center in the UK in the City of London.
.
#ends#